ChemoMetec A/S (CPH:CHEMM) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

It's been a pretty great week for ChemoMetec A/S (CPH:CHEMM) shareholders, with its shares surging 12% to kr.610 in the week since its latest yearly results. It was a credible result overall, with revenues of kr.496m and statutory earnings per share of kr.10.71 both in line with analyst estimates, showing that ChemoMetec is executing in line with expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Following the latest results, ChemoMetec's three analysts are now forecasting revenues of kr.558.3m in 2026. This would be a solid 13% improvement in revenue compared to the last 12 months. Per-share earnings are expected to bounce 21% to kr.12.94. In the lead-up to this report, the analysts had been modelling revenues of kr.563.5m and earnings per share (EPS) of kr.12.85 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

See our latest analysis for ChemoMetec

The analysts reconfirmed their price target of kr.640, showing that the business is executing well and in line with expectations. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on ChemoMetec, with the most bullish analyst valuing it at kr.690 and the most bearish at kr.550 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting ChemoMetec is an easy business to forecast or the the analysts are all using similar assumptions.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 13% growth on an annualised basis. That is in line with its 13% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 9.8% per year. So it's pretty clear that ChemoMetec is forecast to grow substantially faster than its industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at kr.640, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on ChemoMetec. Long-term earnings power is much more important than next year's profits. We have forecasts for ChemoMetec going out to 2028, and you can see them free on our platform here.

You can also see our analysis of ChemoMetec's Board and CEO remuneration and experience, and whether company insiders have been buying stock.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.